Literature DB >> 33971665

A state-of-the-art review of the current role of cardioprotective techniques in cardiac transplantation.

Paul P Cullen1, Steven S Tsui2, Noel M Caplice3, John A Hinchion1.   

Abstract

OBJECTIVES: The use of 'extended criteria' donor hearts and reconditioned hearts from donation after circulatory death has corresponded with an increase in primary graft dysfunction, with ischaemia-reperfusion injury being a major contributing factor in its pathogenesis. Limiting ischaemia-reperfusion injury through optimising donor heart preservation may significantly improve outcomes. We sought to review the literature to evaluate the evidence for this.
METHODS: A review of the published literature was performed to assess the potential impact of organ preservation optimisation on cardiac transplantation outcomes.
RESULTS: Ischaemia-reperfusion injury is a major factor in myocardial injury during transplantation with multiple potential therapeutic targets. Innate survival pathways have been identified, which can be mimicked with pharmacological conditioning. Although incompletely understood, discoveries in this domain have yielded extremely encouraging results with one of the most exciting prospects being the synergistic effect of selected agents. Ex situ heart perfusion is an additional promising adjunct.
CONCLUSIONS: Cardiac transplantation presents a unique opportunity to perfuse the whole heart before, or immediately after, the onset of ischaemia, thus maximising the potential for global cardioprotection while limiting possible systemic side effects. While clinical translation in the setting of myocardial infarction has often been disappointing, cardiac transplantation may afford the opportunity for cardioprotection to finally deliver on its preclinical promise.
© The Author(s) 2021. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Cardiac transplantation; Ischaemia–reperfusion injury; Ischaemic conditioning

Mesh:

Year:  2021        PMID: 33971665      PMCID: PMC8691689          DOI: 10.1093/icvts/ivaa333

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  47 in total

1.  AMISTAD trials: possible reasons for lack of success.

Authors:  Michael V Cohen; James M Downey
Journal:  J Am Coll Cardiol       Date:  2006-02-23       Impact factor: 24.094

Review 2.  The cGMP/PKG pathway as a common mediator of cardioprotection: translatability and mechanism.

Authors:  Javier Inserte; David Garcia-Dorado
Journal:  Br J Pharmacol       Date:  2015-03-16       Impact factor: 8.739

3.  Is red wine a SAFE sip away from cardioprotection? Mechanisms involved in resveratrol- and melatonin-induced cardioprotection.

Authors:  Kim T Lamont; Sarin Somers; Lydia Lacerda; Lionel H Opie; Sandrine Lecour
Journal:  J Pineal Res       Date:  2011-02-23       Impact factor: 13.007

4.  Melatonin protects circulatory death heart from ischemia/reperfusion injury via the JAK2/STAT3 signalling pathway.

Authors:  Hongwen Lan; Yunshu Su; Yakun Liu; Cheng Deng; Jing Wang; Taiqiang Chen; Kouevidjin Ekue Dodzi Jules; Jackson Ferdinand Masau; Huiling Li; Xiang Wei
Journal:  Life Sci       Date:  2019-04-24       Impact factor: 5.037

5.  Heart Transplantation With Donation After Circulatory Death.

Authors:  Petra Niederberger; Emilie Farine; Mathieu Raillard; Monika Dornbierer; Darren H Freed; Stephen R Large; Hong C Chew; Peter S MacDonald; Simon J Messer; Christopher W White; Thierry P Carrel; Hendrik T Tevaearai Stahel; Sarah L Longnus
Journal:  Circ Heart Fail       Date:  2019-04       Impact factor: 8.790

6.  Hearts Donated After Circulatory Death and Reconditioned Using Normothermic Regional Perfusion Can Be Successfully Transplanted Following an Extended Period of Static Storage.

Authors:  Roberto V P Ribeiro; Juglans S Alvarez; Frank Yu; Emanuela Paradiso; Mitchell B Adamson; Giulia Maria Ruggeri; Naoto Fukunaga; Ved Bissoondath; Cyril Serrick; Massimiliano Meineri; Heather Ross; Vivek Rao; Mitesh V Badiwala
Journal:  Circ Heart Fail       Date:  2019-04       Impact factor: 8.790

7.  Elevated Cardiac Troponin I in Preservation Solution Is Associated With Primary Graft Dysfunction.

Authors:  Matthew A Schechter; Michael J Watson; Bryan J Feger; Kevin W Southerland; Rajashree Mishra; Louis R Dibernardo; Maragatha Kuchibhatla; Jacob N Schroder; Mani A Daneshmand; Chetan B Patel; Joseph G Rogers; Carmelo A Milano; Dawn E Bowles
Journal:  J Card Fail       Date:  2015-09-10       Impact factor: 5.712

8.  Cyclosporine A in Reperfused Myocardial Infarction: The Multicenter, Controlled, Open-Label CYCLE Trial.

Authors:  Filippo Ottani; Roberto Latini; Lidia Staszewsky; Luigi La Vecchia; Nicola Locuratolo; Marco Sicuro; Serge Masson; Simona Barlera; Valentina Milani; Mario Lombardi; Alessandra Costalunga; Nadia Mollichelli; Andrea Santarelli; Nicoletta De Cesare; Paolo Sganzerla; Alberto Boi; Aldo Pietro Maggioni; Ugo Limbruno
Journal:  J Am Coll Cardiol       Date:  2016-02-02       Impact factor: 24.094

9.  Sixteen-Hour Ex Vivo Donor Heart Perfusion During Long-Distance Transportation for Heart Transplantation.

Authors:  Rymbay Kaliyev; Serik Bekbossynov; Zhuldyz Nurmykhametova
Journal:  Artif Organs       Date:  2018-12-25       Impact factor: 3.094

10.  Stimulation of soluble guanylate cyclase improves donor organ function in rat heart transplantation.

Authors:  Kálmán Benke; Balázs Tamás Németh; Alex Ali Sayour; Klára Aliz Stark; Attila Oláh; Mihály Ruppert; Gábor Szabó; Sevil Korkmaz-Icöz; Eszter Mária Horváth; Rita Benkő; István Hartyánszky; Zoltán Szabolcs; Béla Merkely; Tamás Radovits
Journal:  Sci Rep       Date:  2020-03-24       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.